Trial marks a major step in the development of innovative treatments for high-risk cardiovascular disease
The research team at ‘Heart and Brain’ Pleven, led by Prof. Iana Simova, has achieved a major milestone in clinical trials with the successful randomisation of Europe’s first patient for the SHASTA-3 clinical trial. The trial, which targets patients with severe familial hypertriglyceridaemia, marks an important step forward in the development of innovative treatments for this high-risk cardiovascular disease.
Familial hypertriglyceridemia (FH) is a genetic disorder that results in dangerously high triglyceride levels and contributes to an increased risk of cardiovascular events. The SHASTA-3 study aims to evaluate the effectiveness of a novel therapeutic approach aimed at reducing triglyceride levels and minimizing associated risks.
In recognition of this achievement, John Montgomery, Chief Executive Officer of Arrowhead Pharmaceuticals, personally congratulated Professor Simova and her team, highlighting the importance of their work in advancing the understanding and treatment of cardiovascular disease.
This trial represents not only a key milestone for Prof. Simova’s team, but also a major milestone for Prof. Simova, but also an important collaboration between academic research and the pharmaceutical industry. It highlights the crucial role that clinical drug trials play in improving patient outcomes and advancing medical science.
